December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In an interim analysis of the randomized phase II OPTIC trial, the maximum benefit:risk ratio with ponatinib was observed with 45-mg starting dose in previously treated CP-CML regardless of mutation status or number of previous TKIs.